摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-isopropoxythiophene | 141811-51-0

中文名称
——
中文别名
——
英文名称
3-isopropoxythiophene
英文别名
3-i-propoxythiophene;3-propan-2-yloxythiophene
3-isopropoxythiophene化学式
CAS
141811-51-0
化学式
C7H10OS
mdl
——
分子量
142.222
InChiKey
VPTGBLKZYFOQJV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    37.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-isopropoxythiophene正丁基锂四甲基乙二胺2-[[三(羟甲基)甲基]氨基]乙磺酸 作用下, 以 乙醚正己烷二氯甲烷 为溶剂, 反应 1.0h, 生成 syn-[2-(3-isopropoxythienyl)]di(1-adamantyl)methane
    参考文献:
    名称:
    Lomas, John S.; Vauthier, Edouard; Vaissermann, Jacqueline, Journal of the Chemical Society. Perkin Transactions 2 (2001), 2000, # 7, p. 1399 - 1408
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-溴噻吩异丙醇 在 copper(I) bromide sodium 作用下, 生成 3-isopropoxythiophene
    参考文献:
    名称:
    卤化铜(I)催化烷基芳基和烷基杂芳基醚的合成
    摘要:
    使用溴化铜(I),由(杂)芳基卤化物(主要是溴化物)和醇钠制备了许多烷基芳基和烷基杂芳基醚。研究了主要溶剂,卤素原子,反应温度和氧的存在对反应速率和选择性的影响。此外,还研究了催化剂的分解和芳基卤化物的还原。
    DOI:
    10.1016/s0040-4020(01)88501-x
点击查看最新优质反应信息

文献信息

  • [EN] TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
    申请人:GLOBAL BLOOD THERAPEUTICS INC
    公开号:WO2019036377A1
    公开(公告)日:2019-02-21
    The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本公开提供了某些三环化合物,它们是组蛋白甲基转移酶G9a和/或GLP抑制剂,因此可用于治疗通过抑制G9a和/或GLP可治疗的疾病,如癌症和血红蛋白病(例如β地中海贫血和镰状细胞病)。还提供了含有这些化合物的药物组合物和制备这些化合物的方法。
  • Hydrogen bonding and steric effects on rotamerization in 3,4-alkylenedioxy-, 3-alkoxy- and 3,4-dialkoxy-2-thienyldi(tert-butyl)methanols: an NMR, IR and X-ray crystallographic studyElectronic supplementary information (ESI) available: NMR data; activation parameters for rotation; MMFF94 steric energies and alkoxy group geometries; thermodynamic data; quantum mechanical calculations of geometries; bond lengths, bond angles and torsion angles of 8A-Et; NMR and IR data on new compounds. See http://www.rsc.org/suppdata/p2/b1/b109612p/
    作者:John S. Lomas、Alain Adenier、Kun Gao、François Maurel、Jacqueline Vaissermann
    DOI:10.1039/b109612p
    日期:2002.1.23
    largely determined by steric effects but intramolecular hydrogen bonding in the anti isomer contributes to the variation of the anti → syn rotation barrier. A single crystal X-ray diffraction study of the anti-3,4-diethoxy derivative shows that the orientation of the 3-alkoxy group is very different from that in anti-3-methoxy-2-thienyldi(1-adamantyl)methanol. Molecular mechanics and quantum mechanical calculations
    的平衡常数的抗 ↔ 顺rotamerization(反:分子内氢键键合的羟基; syn:“免费”羟基3,4-亚烷基二氧基-,3-烷氧基-和3,4-二烷氧基-2-噻吩基二(叔丁基)甲醇的-)取决于3,4-亚烷基二氧基或烷氧基和溶剂, 氢键 溶剂 例如DMSO和 吡啶支持顺式异构体。平衡常数([ syn ] / [ anti ])在氯仿 和 苯降低的顺序:3,4-OCH 2 O-,3,4-O-(CH 2)2 O-,3- OME,3- OET,3,4-(OME)2 ≈3-O我-Pr 3,4-(OEt)2,范围超过约2.5个数量级。IR OH拉伸频率的变化和核磁共振 哦 质子反异构体的位移表明分子内氢键以大致相同的顺序增加。该SYN → 抗旋转屏障二甲基亚砜随取代基的大小和数量增加。3,4-亚甲基二氧基噻吩衍生物的势垒(17.5 kcal mol -1)比所有其他衍生物(21.0-22.3 kcal
  • Rate and equilibrium effects of tert-alkyl groups on rotamerization in 3,4-alkylenedioxy-, 3-alkoxy- and 3,4-dialkoxy-2-thienyl(di-tert-alkyl)methanols: an IR, NMR, kinetics and MM studyElectronic supplementary information (ESI) available: additional experimental data. See http://www.rsc.org/suppdata/p2/b2/b203714a/
    作者:John S. Lomas、Alain Adenier
    DOI:10.1039/b203714a
    日期:2002.6.27
    rate-equilibrium relationship. Molecular mechanics calculations (MMFF94 force field) account fairly well for the variation in the free energy difference for rotamer pairs of the di-1-adamantyl, (1-adamantyl)(tert-butyl) and di-tert-butyl derivatives, but slightly overestimate the small differences in the equilibrium constants for the three series. The calculated rotation barriers for the di-tert-butyl compounds
    将二-1-金刚烷基和(1-金刚烷基)(叔丁基)类似物与先前研究的3-或3-和4-取代的2-噻吩基(二叔丁基)甲醇进行了比较。的平衡常数为顺-反rotamerization([顺] / [反])比对于较小的二-稍大叔丁基衍生物。在分子内氢键合的抗旋转异构体中,1 H NMR位移都没有。羟基 质子 也不是OH拉伸频率 指标分子内氢键强度的变化很大程度上受叔烷基基团变化的影响;因此,平衡常数的这些变化必须归因于空间效应的变化。具有较大叔烷基基团的化合物的旋转壁垒得到大大增强和更好的区分。在所有三组中,syn → anti和anti → syn旋转势垒是线性相关的,任何一个都可以与自由能差相关。但是,数据不符合经典的Leffler-Grunwald型速率-平衡关系的标准。分子力学计算(MMFF94力场)很好地说明了二-1-金刚烷基,(1-金刚烷基)(叔丁基)和二叔丁基衍生物的旋转异构体对的自由能差
  • PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    申请人:Allen Shelley
    公开号:US20150166564A1
    公开(公告)日:2015-06-18
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    化合物I的公式:或其立体异构体、互变异构体、药学上可接受的盐、溶剂或前药,其中R1、R2、Ra、Rb、Rc、Rd、X、Y、B和环C的定义如本文所述,其中Y-B基团和NH-C(═X)-NH基团处于反式构象,是TrkA激酶的抑制剂,可用于治疗可以通过TrkA激酶抑制剂治疗的疾病,例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
  • PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    申请人:Array BioPharma Inc.
    公开号:US20170217936A1
    公开(公告)日:2017-08-03
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
查看更多